$3.79 Billion is the total value of Camber Capital Management LP's 70 reported holdings in Q3 2020. The portfolio turnover from Q2 2020 to Q3 2020 was 53.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CHNG | Buy | CHANGE HEALTHCARE INC | $435,300,000 | +144.4% | 30,000,000 | +88.7% | 11.48% | +12.7% |
| MYL | Buy | MYLAN N V | $355,920,000 | +101.2% | 24,000,000 | +118.2% | 9.39% | -7.2% |
| ALXN | Buy | ALEXION PHARMACEUTICALS INC | $297,518,000 | +89.3% | 2,600,000 | +85.7% | 7.85% | -12.7% |
| PRGO | Buy | PERRIGO CO PLC | $261,688,000 | +110.4% | 5,700,000 | +153.3% | 6.90% | -3.0% |
| UHS | Buy | UNIVERSAL HLTH SVCS INCcl b | $246,146,000 | +165.0% | 2,300,000 | +130.0% | 6.49% | +22.1% |
| ALKS | Buy | ALKERMES PLC | $240,266,000 | +70.8% | 14,500,000 | +100.0% | 6.34% | -21.3% |
| HCA | New | HCA HEALTHCARE INC | $180,786,000 | – | 1,450,000 | +100.0% | 4.77% | – |
| BHC | New | BAUSCH HEALTH COS INC | $139,860,000 | – | 9,000,000 | +100.0% | 3.69% | – |
| IRWD | Buy | IRONWOOD PHARMACEUTICALS INC | $130,428,000 | +94.4% | 14,500,000 | +123.1% | 3.44% | -10.4% |
| MYGN | Buy | MYRIAD GENETICS INC | $130,400,000 | +187.5% | 10,000,000 | +150.0% | 3.44% | +32.5% |
| SRPT | Buy | SAREPTA THERAPEUTICS INC | $119,366,000 | +86.1% | 850,000 | +112.5% | 3.15% | -14.2% |
| BLUE | Buy | BLUEBIRD BIO INC | $118,690,000 | +52.5% | 2,200,000 | +72.5% | 3.13% | -29.7% |
| Buy | PACIFIC BIOSCIENCES CALIF IN | $87,054,000 | +711.3% | 8,820,000 | +183.6% | 2.30% | +273.9% | |
| CI | New | CIGNA CORP NEW | $84,706,000 | – | 500,000 | +100.0% | 2.23% | – |
| COLL | Buy | COLLEGIUM PHARMACEUTICAL INC | $83,280,000 | +137.9% | 4,000,000 | +100.0% | 2.20% | +9.7% |
| NKTR | Buy | NEKTAR THERAPEUTICS | $82,950,000 | +19.4% | 5,000,000 | +66.7% | 2.19% | -45.0% |
| AMAG | Buy | AMAG PHARMACEUTICALS INC | $82,532,000 | +145.7% | 8,780,000 | +100.0% | 2.18% | +13.3% |
| TEVA | Buy | TEVA PHARMACEUTICAL INDS LTDsponsored ads | $81,090,000 | +228.8% | 9,000,000 | +350.0% | 2.14% | +51.6% |
| CHRS | Buy | COHERUS BIOSCIENCES INC | $80,696,000 | +105.4% | 4,400,000 | +100.0% | 2.13% | -5.3% |
| BKD | Buy | BROOKDALE SR LIVING INC | $76,200,000 | +72.2% | 30,000,000 | +100.0% | 2.01% | -20.6% |
| OSUR | New | ORASURE TECHNOLOGIES INC | $66,936,000 | – | 5,500,000 | +100.0% | 1.76% | – |
| BMRN | New | BIOMARIN PHARMACEUTICAL INC | $60,864,000 | – | 800,000 | +100.0% | 1.60% | – |
| PBYI | Buy | PUMA BIOTECHNOLOGY INC | $51,560,000 | +106.0% | 5,110,000 | +112.9% | 1.36% | -5.0% |
| THC | New | TENET HEALTHCARE CORP | $49,020,000 | – | 2,000,000 | +100.0% | 1.29% | – |
| RDUS | Buy | RADIUS HEALTH INC | $47,062,000 | +820.8% | 4,150,000 | +1006.7% | 1.24% | +325.0% |
| AVRO | Buy | AVROBIO INC | $46,872,000 | +99.0% | 3,600,000 | +166.7% | 1.24% | -8.3% |
| ATRA | Buy | ATARA BIOTHERAPEUTICS INC | $36,288,000 | +77.9% | 2,800,000 | +100.0% | 0.96% | -18.0% |
| GSK | Sell | GLAXOSMITHKLINE PLCsponsored adr | $33,876,000 | -72.3% | 900,000 | -70.0% | 0.89% | -87.2% |
| IMVT | Buy | IMMUNOVANT INC | $30,882,000 | +58.5% | 877,600 | +9.7% | 0.81% | -27.0% |
| DRNA | New | DICERNA PHARMACEUTICALS INC | $18,890,000 | – | 1,050,000 | +100.0% | 0.50% | – |
| GLYC | Buy | GLYCOMIMETICS INC | $15,350,000 | +36.1% | 5,000,000 | +66.7% | 0.40% | -37.2% |
| STRO | Buy | SUTRO BIOPHARMA INC | $12,060,000 | +159.0% | 1,200,000 | +100.0% | 0.32% | +19.5% |
| GBT | New | GLOBAL BLOOD THERAPEUTICS IN | $5,514,000 | – | 100,000 | +100.0% | 0.14% | – |
| VIR | New | VIR BIOTECHNOLOGY INC | $565,000 | – | 16,464 | +100.0% | 0.02% | – |
| VIRC | New | VIRCO MFG CO | $565,000 | – | 16,464 | +100.0% | 0.02% | – |
| ANGO | New | ANGIODYNAMICS INC | $504,000 | – | 41,752 | +100.0% | 0.01% | – |
| MNTA | Exit | MOMENTA PHARMACEUTICALS INC | $0 | – | -450,000 | -100.0% | -0.86% | – |
| TBIO | Exit | TRANSLATE BIO INC | $0 | – | -1,000,000 | -100.0% | -1.02% | – |
| SAGE | Exit | SAGE THERAPEUTICS INC | $0 | – | -525,000 | -100.0% | -1.25% | – |
| GKOS | Exit | GLAUKOS CORP | $0 | – | -730,000 | -100.0% | -1.60% | – |
| ASND | Exit | ASCENDIS PHARMA A Ssponsored adr | $0 | – | -350,000 | -100.0% | -2.96% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEVA PHARMACEUTICALS INDS LTD | 34 | Q3 2023 | 9.7% |
| BROOKDALE SR LIVING INC | 32 | Q3 2023 | 5.0% |
| PERRIGO CO PLC | 29 | Q3 2023 | 7.1% |
| TENET HEALTHCARE CORP | 28 | Q3 2023 | 8.5% |
| NEKTAR THERAPEUTICS | 28 | Q1 2022 | 9.8% |
| UNIVERSAL HLTH SVCS INC | 25 | Q3 2023 | 9.9% |
| MYRIAD GENETICS INC | 24 | Q3 2023 | 5.0% |
| SAREPTA THERAPEUTICS INC | 23 | Q3 2023 | 6.0% |
| MYLAN NV | 21 | Q3 2020 | 10.1% |
| AMAG PHARMACEUTICALS INC | 21 | Q3 2020 | 4.0% |
View Camber Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC | February 02, 2023 | ? | ? |
| Solid Biosciences Inc. | December 12, 2022 | ? | ? |
| AVROBIO, Inc. | February 14, 2022 | ? | ? |
| COLLEGIUM PHARMACEUTICAL, INC | February 14, 2022 | ? | ? |
| AMAG PHARMACEUTICALS, INC. | February 16, 2021 | ? | ? |
| Atara Biotherapeutics, Inc. | February 16, 2021 | ? | ? |
| Change Healthcare Inc. | February 16, 2021 | ? | ? |
| GLYCOMIMETICS INC | February 16, 2021 | ? | ? |
| Clovis Oncology, Inc. | February 14, 2020 | ? | ? |
| Cyclerion Therapeutics, Inc. | February 14, 2020 | ? | ? |
View Camber Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-30 |
| 13F-HR | 2023-08-14 |
View Camber Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.